Effect of dupilumab on sputum eosinophils in patients with moderate-to-severe asthma

Allergy. 2024 Feb;79(2):509-513. doi: 10.1111/all.15901. Epub 2023 Sep 26.

Authors

Sarah Svenningsen^{1

2}, Melanie Kjarsgaard^{1

2}, Kayla Zhang¹, Hana Serajeddini^{1

2}, Carmen Venegas Garrido^{1

2}, Anurag Bhalla^{1

2}, Katherine Radford¹, Chynna Huang¹, Terence Ho^{1

2}, Nandhitha Ragunayakam¹, Ashutosh Thakar¹, Nisarg Radadia¹, Manali Mukherjee^{1

2}, Parameswaran Nair^{1

2}

Affiliations

¹ Firestone Institute for Respiratory Health, Hamilton, Ontario, Canada.
² Department of Medicine, McMaster University, Hamilton, Ontario, Canada.

PMID: 37750593
DOI: 10.1111/all.15901

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Monoclonal, Humanized / pharmacology
Antibodies, Monoclonal, Humanized / therapeutic use
Asthma* / diagnosis
Asthma* / drug therapy
Eosinophils*
Humans
Sputum

Substances

dupilumab
Antibodies, Monoclonal, Humanized

Grants and funding